ClinicalTrials.gg
RecruitingNCT06793371AMBER-HFpEFUpdated Aug 27, 2026

AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF

A Phase 2 interventional study of CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg) and Placebo to match CK-4021586 in Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF), sponsored by Cytokinetics. Recruiting at 26 sites in United States. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Cytokinetics · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 15 studies in Heart Failure by Cytokinetics — 2 open to participants now, 2 under way, 1 of them phase 3. Heart Failure · Cytokinetics.

Planned enrollment
7th of 15
60 · median 50
Started
2025
the only one that year
Phase 2
8 of 15
1 open now
Registered
15th of 15
by date

Among the 15 studies in Heart Failure by Cytokinetics, this one is the 7th largest by planned enrollment, is the only one that started in 2025, is one of 8 in phase 2, and was the 15th registered.

Heart Failure

6,339 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

2 of the 15 studies in Heart Failure by Cytokinetics are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Heart Failure by Cytokinetics, or all of them as a file.
02

Study summary

This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF.

03

Conditions studied

  • Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)

Browse trials for

Keywords

  • Symptomatic heart failure with preserved ejection fraction
  • HFpEF
  • Heart failure
  • CK-4021586
  • CK-586
  • AMBER-HFpEF
  • AMBER
  • Cardiac myosin inhibitor
  • CMI
  • CY 9021
  • ulacamten
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males and females ≥ 40 years and ≤ 85 years of age at screening.
  • Diagnosed with HF with functional class II or III.
  • Screening echocardiography with ≥ 60%.
  • Screening NT-proBNP ≥ 300 pg/mL for participants in sinus rhythm and ≥ 900 pg/mL for participants with comorbid atrial fibrillation or flutter.
  • \< 40 kg/m2.
  • Participants on beta-blockers, angiotensin-converting enzyme (ACE)/angiotensin II receptor blocker (ARB) or angiotensin receptor/neprilysin inhibitor (ARNI), must be on stable doses for more than 30 days prior to screening.
  • Participants on a glucagon-like peptide-1 (GLP-1) agonist must be on a stable dose for more than 24 weeks prior to screening with no anticipated plans to change dose during this study.

Exclusion criteria

Exclusion Criteria:

  • History or evidence of any other disorder, , active infection, other condition, or disease that, in the opinion of the investigator or the Medical Monitor, would pose a risk to patient safety or interfere with the study evaluation, procedures, or completion.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    CK-4021586 - Cohort 1

    Participants may receive 150 mg or 300 mg of CK-4021586 daily, guided by echocardiography assessments, for 12 weeks total.

    Drug: CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)

  • Placebo comparator
    Placebo - Cohort 1

    Participants will receive placebo daily for up to 12 weeks.

    Drug: Placebo to match CK-4021586

  • Experimental
    CK-4021586 - Cohort 2

    Participants may receive 300 mg or 450 mg of CK-4021586 daily, guided by echocardiography assessments, for 12 weeks total.

    Drug: CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)

  • Placebo comparator
    Placebo - Cohort 2

    Participants will receive placebo daily for up to 12 weeks.

    Drug: Placebo to match CK-4021586

  • Experimental
    CK-4021586 - Cohort 3

    Participants may receive 450 mg or 600 mg of CK-4021586 daily, guided by echocardiography assessments, for 12 weeks total.

    Drug: CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)

  • Placebo comparator
    Placebo - Cohort 3

    Participants will receive placebo daily for up to 12 weeks.

    Drug: Placebo to match CK-4021586

Interventions

  • DrugCK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)

    CK-4021586 administered orally

    Also known as: ulacamten

  • DrugPlacebo to match CK-4021586

    Placebo administered orally

06

What researchers measure

Primary outcomes

  1. Incidence of early drug discontinuation

    Incidence of early drug discontinuation observed during dosing of CK 4021586 in patients with HFpEF

    Time frame: 12 weeks

  2. Incidence of LVEF < 40%

    Incidence of left-ventricular ejection fraction (LVEF) \< 40% observed during dosing of CK-4021586 in patients with HFpEF

    Time frame: 12 weeks

  3. Incidence of AEs

    Incidence of adverse events observed during dosing of CK-4021586 in patients with HFpEF

    Time frame: 12 weeks

Secondary outcomes

  1. Change in NT-proBNP

    Change from baseline values in NT-proBNP to Week 6 and Week 12

    Time frame: Baseline to Week 6 and Week 12

  2. Plasma concentrations of CK-4021586

    Observed 2-hour post dose plasma concentration (C2hr) and minimum plasma concentration (Cmin) for CK-4021586 over the dosing interval

    Time frame: 12 weeks

  3. Concentration-response relationship of CK-4021586 on NT-proBNP change

    Slope of the relationship of plasma concentration of CK-4021586 to the change from baseline in the NT-proBNP

    Time frame: Baseline to Week 12

  4. Concentration-response relationship of CK-4021586 to LVEF change

    Slope of the relationship of plasma concentration of CK-4021586 to the change from baseline in the LVEF

    Time frame: Baseline to Week 12

  5. Change in LVEF

    Change from baseline in LVEF at Week 6 and Week 12

    Time frame: Baseline to Week 6 and Week 12

07

Study locations

24 of 26 sites recruiting
  • Eastern Shore Research Institute, LLC
    Fairhope, Alabama 36532, United States
    Recruiting
  • University of Arizona Sarver Heart Center
    Tucson, Arizona 85724, United States
    Recruiting
  • John L. McClellan Memorial Veterans Hospital
    Little Rock, Arkansas 72205, United States
    Recruiting
  • BioSolutions Clinical Research Center
    Imperial, California 92251, United States
    Recruiting
  • Profound Research LLC
    Pasadena, California 91105, United States
    Recruiting
  • University of California, San Francisco - Heart and Vascular Center
    San Francisco, California 94143, United States
    Recruiting
  • FOMAT - Comprehensive Cardiovascular Care
    Santa Maria, California 93454, United States
    Recruiting
  • Blue Coast Research Center, LLC
    Vista, California 92081, United States
    Recruiting
  • Las Mercedes Medical Research
    Hialeah, Florida 33012, United States
    Recruiting
  • New Generation of Medical Research
    Hialeah, Florida 33016, United States
    Recruiting
  • Cleveland Clinic Florida
    Weston, Florida 33331, United States
    Recruiting
  • Methodist Medical Center of Illinois
    Peoria, Illinois 61636, United States
    Recruiting
  • Louisiana Heart Center
    Slidell, Louisiana 70458, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Massachusetts General Hospital
    Boston, Massachusetts 02214, United States
    Recruiting
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
    Recruiting
  • Washington University Center for Advanced Medicine
    St Louis, Missouri 63110, United States
    Recruiting
  • Morristown Medical Center
    Morristown, New Jersey 07960, United States
    Recruiting
  • NYU Langone Health
    New York, New York 10016, United States
    Recruiting
  • Mount Sinai West
    New York, New York 10019, United States
    Recruiting
  • The Lindner Center for Research & Education at The Christ Hospital
    Cincinnati, Ohio 45219, United States
    Recruiting
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
    Recruiting
  • University of Texas Southwestern Medical Center, Dallas
    Dallas, Texas 75390, United States
    Recruiting
  • Center for Advanced Heart Failure
    Houston, Texas 77030, United States
    Recruiting
  • DelRicht Research
    Vienna, Virginia 22182, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Swedish Heart & Vascular Institute, Advanced Cardiac Support Program
    Seattle, Washington 98122, United States
    Recruiting
  • Froedtert Hospital - Center for Advanced Care
    Milwaukee, Wisconsin 53226, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Sep 2026, 19 months after the start.

Of 74 industry-sponsored phase 2 interventional studies under Heart Failure, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 31. This study's planned 19 months is close to that.

Counting every sponsor, half of 185 studies reached it within 29 months; a quarter within 17 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2025
First posted
Jan 27, 2025
StartActual
Feb 6, 2025
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2026
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06793371
Lead sponsor
Cytokinetics
Responsible party
Sponsor
First posted
Jan 27, 2025
Start date
Feb 6, 2025
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Aug 27, 2026

Study contacts

Cytokinetics MD
Contact
medicalaffairs@cytokinetics.com
650-624-2929
Cytokinetics MD
study director · Cytokinetics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion